Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

stada, lda. - losartan + hidroclorotiazida - comprimido revestido por película - 50 mg + 12.5 mg - losartan de potássio 50 mg ; hidroclorotiazida 12.5 mg - losartan and diuretics - genérico - duração do tratamento: longa duração

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

stada, lda. - losartan + hidroclorotiazida - comprimido revestido por película - 50 mg + 12.5 mg - losartan de potássio 50 mg ; hidroclorotiazida 12.5 mg - losartan and diuretics - genérico - duração do tratamento: longa duração

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

stada, lda. - losartan + hidroclorotiazida - comprimido revestido por película - 100 mg + 25 mg - hidroclorotiazida 25 mg ; losartan de potássio 100 mg - losartan and diuretics - genérico - duração do tratamento: longa duração

União Europeia - português - EMA (European Medicines Agency)

stada arzneimittel ag - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - agentes antineoplásicos - oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. para mais informações sobre o status do receptor do fator de crescimento epidérmico humano (her2), consulte a seção 5. oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with oyavas in combination with capecitabine. para mais informações sobre o status her2, consulte a seção 5. oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

stada, lda. - sorafenib - comprimido revestido por película - 200 mg - sorafenib, tosilato 274 mg - sorafenib - genérico - duração do tratamento: longa duração

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

stada, lda. - sunitinib - cápsula - 12.5 mg - sunitinib 12.5 mg - sunitinib - genérico - duração do tratamento: longa duração

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

stada, lda. - sunitinib - cápsula - 50 mg - sunitinib 50 mg - sunitinib - genérico - duração do tratamento: longa duração

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

stada, lda. - sunitinib - cápsula - 25 mg - sunitinib 25 mg - sunitinib - genérico - duração do tratamento: longa duração

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

stada, lda. - sunitinib - cápsula - 25 mg - sunitinib 25 mg - sunitinib - genérico - duração do tratamento: longa duração

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

stada, lda. - sunitinib - cápsula - 12.5 mg - sunitinib 12.5 mg - sunitinib - genérico - duração do tratamento: longa duração